Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects.
about
Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional studyBiomarkers and potential mechanisms of obesity-induced oxidant stress in humans.Free fatty acids exert a greater effect on ocular and skin blood flow than triglycerides in healthy subjects.Endothelial dysfunction as a target for prevention of cardiovascular disease.Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetesVascular reactivity in diabetes mellitus.Endothelium, inflammation, and diabetes.Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor γ expression.The impact of antidiabetic therapies on cardiovascular disease.18β-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARγ and Nrf2 upregulationEffect of troglitazone on radiation sensitivity in cervix cancer cells.Cardiovascular redox and ox stress proteomics.Cardiovascular effects of the thiazolidinediones.PPAR Agonists and Cardiovascular Disease in Diabetes.Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity.Role of inflammation and endothelial dysfunction in the pathogenesis of cardiac syndrome X.Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.The in vitro effects of superoxide, some commercially available antioxidants and red palm oil on sperm motility.The thiazolidinedione controversy in cardiovascular risk.Statins and modulation of oxidative stress.Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins.C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice.Vascular endothelial dysfunction tested by blunted response to endothelium-dependent vasodilation by salbutamol and its related factors in uncomplicated pre-menopausal obese women.The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.Thiazolidinediones : beyond glycemic control.Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
P2860
Q21195169-5C69DE7E-E517-4E4F-B69B-FD7CFEF9D6C7Q30438756-91454C8E-06B8-481C-8092-69C3F222E199Q33205786-B14957F7-9780-40A9-8FF7-B475E81779C6Q33610670-F9D32DF7-1D82-4623-BE6B-0CB799C73906Q34509903-8810F512-B8CC-461A-84A3-E7AB69BA8597Q35087606-CCC0677D-8951-4AC1-968C-BA616BA3838FQ35087609-44E72615-84C0-4464-8508-4911046AA803Q35992073-7FE79A8D-E0D6-41D3-83C6-98BA1A50CFCCQ36025991-E1B27988-95FD-4CCC-9D5E-95DD94FEBDC7Q36074465-0BE2DC3C-DC36-4B4D-B22D-03821BFC7EB3Q36195948-DC33C817-31AB-49C0-A4B5-1AC2C2E384B2Q36252927-22FA8FD0-2444-40F2-9931-8B6473DC8D6FQ36268105-87ACC1CC-BBDB-4BBB-B4AB-B7693BFA1F75Q36444975-0EDAC38E-EF22-47DC-8606-F698DDD9405EQ36567768-339B281E-F753-41B6-BA5B-C8DA453952EDQ36966082-73DA0322-13DB-44F0-A16B-5857C5063E80Q37608505-41379FA1-8CB7-4B15-99D3-28445EEF6335Q37624307-EDDD8C48-F325-4238-A451-059524888BF3Q38460480-7003AEEC-A53C-4783-9CF7-19B994481F8FQ42141360-3184A085-7C85-4955-B9C8-9C587AA9B94FQ42879737-043F5528-FF7B-4A57-AE3A-87B6DC89D633Q43215640-A3CAE283-2E5E-45EA-9A3D-69772ADF0814Q44582172-6B5274BB-1656-4998-B5F6-D66783255CA3Q44990813-EF1BC668-6AE1-4B89-8ED1-53039A18FB76Q44990872-4E140B10-BFF6-4ED6-8C59-FDD8881B670AQ45166960-898A936B-24D4-445F-933D-41EA82F8FBC3Q46669792-1BFA4C59-F384-445D-BD2F-78357E23C9F1Q46701051-D2A4E3E4-09D3-4093-AFED-A96C64F7FC76Q46882022-66AE1B96-998C-4075-93D2-602A0DB0F5DEQ51482875-C9267049-B8B4-41E2-B333-6E41FE989F1D
P2860
Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Troglitazone reduces reactive ...... odilatation in obese subjects.
@en
Troglitazone reduces reactive ...... odilatation in obese subjects.
@nl
type
label
Troglitazone reduces reactive ...... odilatation in obese subjects.
@en
Troglitazone reduces reactive ...... odilatation in obese subjects.
@nl
prefLabel
Troglitazone reduces reactive ...... odilatation in obese subjects.
@en
Troglitazone reduces reactive ...... odilatation in obese subjects.
@nl
P2093
P356
P1433
P1476
Troglitazone reduces reactive ...... odilatation in obese subjects.
@en
P2093
Y Kumbkarni
P304
P356
10.1161/01.HYP.36.3.430
P407
P577
2000-09-01T00:00:00Z